慢性病性贫血

Roy CN. Anemia of inflammation. Hematology Am Soc Hematol Educ Program. 2010;2010:276-80.

• 全文
• 摘要

Kautz L, Jung G, Nemeth E, et al. Erythroferrone contributes to recovery from anemia of inflammation. Blood. 2014 Oct 16;124(16):2569-74.

• 全文
• 摘要

Kautz L, Jung G, Valore EV, et al. Identification of erythroferrone as an erythroid regulator of iron metabolism. Nat Genet. 2014 Jul;46(7):678-84.

• 全文
• 摘要

Jelkmann W. Developments in the therapeutic use of erythropoiesis stimulating agents. Br J Haematol. 2008 May;141(3):287-97.

• 摘要

Schrijvers D, De Samblanx H, Roila F; ESMO Guidelines Working Group. Erythropoiesis-stimulating agents in the treatment of anaemia in cancer patients: ESMO clinical practice guidelines for use. Ann Oncol. 2010 May;21(suppl 5):v244-7.

• 全文
• 摘要

1.  Roy CN. Anemia of inflammation. Hematology Am Soc Hematol Educ Program. 2010;2010:276-80.

• 全文
• 摘要

2.  Guralnik JM, Eisenstaedt RS, Ferrucci L, et al. Prevalence of anemia in persons 65 years and older in the United States: Evidence for a high rate of unexplained anemia. Blood. 2004 Oct 15;104(8):2263-8.

• 全文
• 摘要

3.  Peeters HR, Jongen-Lavrencic M, Raja AN, et al. Course and characteristics of anaemia in patients with rheumatoid arthritis of recent onset. Ann Rheum Dis. 1996 Mar;55(3):162-8.

• 全文
• 摘要

4.  Van Iperen CE, van de Wiel A, Marx JJ. Acute event-related anaemia. Br J Haematol. 2001 Dec;115(4):739-43.

• 摘要

5.  Walsh TS, Saleh EE, Lee RJ, et al. The prevalence and characteristics of anaemia at discharge home after intensive care. Intensive Care Med. 2006 Aug;32(8):1206-13.

• 摘要

6.  Wong P, Intragumtornchai T. Hospital-acquired anemia. J Med Assoc Thai. 2006 Jan;89(1):63-7.

• 摘要

7.  Weiss G, Goodnough LT. Anemia of chronic disease. N Engl J Med. 2005 Mar 10;352(10):1011-23.

• 摘要

8.  Moldawer LL, Marano MA, Wei H, et al. Cachectin/tumor necrosis factor-alpha alters red blood cell kinetics and induces anemia in vivo. FASEB J. 1989 Mar;3(5):1637-43.

• 摘要

9.  Spivak J. Iron and the anemia of chronic disease. Oncology (Williston Park). 2002 Sep;16(9 suppl 10):25-33.

• 摘要

10.  Roy CN, Andrews NC. Anemia of inflammation: the hepcidin link. Curr Opin Hematol. 2005 Mar;12(2):107-11.

• 摘要

11.  Lee P, Peng H, Gelbart T, et al. Regulation of hepcidin transcription by interleukin-1 and interleukin-6. Proc Natl Acad Sci U S A. 2005 Feb 8;102(6):1906-10.

• 全文
• 摘要

12.  Torti FM, Torti SV. Regulation of ferritin genes and protein. Blood. 2002 May 15;99(10):3505-16.

• 全文
• 摘要

13.  Ludwiczek S, Aigner E, Theurl I, et al. Cytokine-mediated regulation of iron transport in human monocytic cells. Blood. 2003 May 15;101(10):4148-54.

• 全文
• 摘要

14.  Nemeth E, Rivera S, Gabayan V, et al. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest. 2004 May;113(9):1271-6.

• 全文
• 摘要

15.  Kautz L, Jung G, Nemeth E, et al. Erythroferrone contributes to recovery from anemia of inflammation. Blood. 2014 Oct 16;124(16):2569-74.

• 全文
• 摘要

16.  Kautz L, Jung G, Valore EV, et al. Identification of erythroferrone as an erythroid regulator of iron metabolism. Nat Genet. 2014 Jul;46(7):678-84.

• 全文
• 摘要

17.  Taniguchi S, Dai CH, Price JO, et al. Interferon gamma downregulates stem cell factor and erythropoietin receptors but not insulin-like growth factor-I receptors in human erythroid colony-forming cells. Blood. 1997 Sep 15;90(6):2244-52.

• 全文
• 摘要

18.  Smith DL. Anemia in the elderly. Am Fam Physician. 2000 Oct 1;62(7):1565-72.

• 全文
• 摘要

19.  Ludwig H, Fritz E, Kotzmann H, et al. Erythropoietin treatment of anemia associated with multiple myeloma. N Engl J Med. 1990 Jun 14;322(24):1693-9.

• 全文
• 摘要

20.  Steensma DP, Tefferi A. Anemia in the elderly: how should we define it, when does it matter, and what can be done? Mayo Clin Proc. 2007 Aug;82(8):958-66.

• 摘要

21.  Tefferi A. Anemia in adults: a contemporary approach to diagnosis. Mayo Clin Proc. 2003 Oct;78(10):1274-80.

• 摘要

22.  Beutler E, Hoffbrand A, Cook JD. Iron deficiency and overload. Hematology Am Soc Hematol Educ Program. 2003;40-61.

• 全文
• 摘要

23.  Punnonen K, Irjala K, Rajamaki A. Serum transferrin receptor and its ratio to serum ferritin in the diagnosis of iron deficiency. Blood. 1997 Feb 1;89(3):1052-7.

• 全文
• 摘要

24.  Nardone DA, Roth KM, Mazur DJ, et al. Usefulness of physical examination in detecting the presence or absence of anemia. Arch Intern Med. 1990 Jan;150(1):201-4.

• 摘要

25.  Gjorup T, Bugge PM, Hendriksen C, et al. A critical evaluation of the clinical diagnosis of anemia. Am J Epidemiol. 1986 Oct;124(4):657-65.

• 摘要

26.  Hung OL, Kwon NS, Cole AE, et al. Evaluation of the physician's ability to recognize the presence or absence of anemia, fever, and jaundice. Acad Emerg Med. 2000 Feb;7(2):146-56.

• 全文
• 摘要

27.  Sheth TN, Choudhry NK, Bowes M, et al. The relation of conjunctival pallor to the presence of anemia. J Gen Intern Med. 1997 Feb;12(2):102-6.

• 全文
• 摘要

28.  Spivak JL. Recombinant human erythropoietin and the anemia of cancer. Blood. 1994 Aug 15;84(4):997-1004.

• 全文
• 摘要

29.  Pincus T, Olsen NJ, Russell IJ, et al. Multicenter study of recombinant human erythropoietin in correction of anemia in rheumatoid arthritis. Am J Med. 1990 Aug;89(2):161-8.

• 摘要

30.  Henry DH, Beall GN, Benson CA, et al. Recombinant human erythropoietin in the treatment of anemia associated with human immunodeficiency virus (HIV) infection and zidovudine therapy. Overview of four clinical trials. Ann Intern Med. 1992 Nov 1;117(9):739-48.

• 摘要

31.  Ludwig H, Fritz E, Leitgeb C, et al. Prediction of response to erythropoietin treatment in chronic anemia of cancer. Blood. 1994 Aug 15;84(4):1056-63.

• 全文
• 摘要

32.  Osterborg A, Brandberg Y, Molostova V, et al. Randomized, double-blind, placebo-controlled trial of recombinant human erythropoietin, epoetin Beta, in hematologic malignancies. J Clin Oncol. 2002 May 15;20(10):2486-94.

• 摘要

33.  Moreland LW, Baumgartner SW, Schiff MH, et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med. 1997 Jul 17;337(3):141-7.

• 全文
• 摘要

34.  KDIGO Anemia Work Group. KDIGO clinical practice guideline for anemia in chronic kidney disease. Kidney Int Suppl. 2012;2:279-335.

• 全文

35.  Weinberg ED. Iron loading and disease surveillance. Emerg Infect Dis. 1999 May-Jun;5(3):346-52.

• 全文
• 摘要

36.  Rizzo JD, Brouwers M, Hurley P, et al. American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer. J Oncol Pract. 2010 Nov;6(6):317-20.

• 全文
• 摘要

37.  National Institute for Health and Care Excellence. Erythropoiesis‑stimulating agents (epoetin and darbepoetin) for treating anaemia in people with cancer having chemotherapy. November 2014 [internet publication].

• 全文

38.  Canadian Agency for Drugs and Technologies in Health. Overview of systematic review and economic evaluation of erythropoiesis-stimulating agents for anemia of cancer or of chemotherapy. April 2009 [internet publication].

• 全文

39.  Bokemeyer C, Aapro MS, Courdi A, et al. EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update. Eur J Cancer. 2007 Jan;43(2):258-70.

• 摘要

40.  Zarychanski R, Houston DS. Anemia of chronic disease: a harmful disorder or an adaptive, beneficial response? CMAJ. 2008 Aug 12;179(4):333-7.

• 全文
• 摘要

41.  Leyland-Jones B, Bondarenko I, Nemsadze G, et al. A randomized, open-label, multicenter, phase III study of epoetin alfa versus best standard of care in anemic patients with metastatic breast cancer receiving standard chemotherapy. J Clin Oncol. 2016 Apr 10;34(11):1197-207.

• 摘要

42.  Crathorne L, Huxley N, Haasova M, et al. The effectiveness and cost-effectiveness of erythropoiesis-stimulating agents (epoetin and darbepoetin) for treating cancer treatment-induced anaemia (including review of technology appraisal no. 142): a systematic review and economic model. Health Technol Assess. 2016 Feb;20(13):1-588.

• 摘要

43.  Mhaskar R, Wao H, Miladinovic B, et al. The role of iron in the management of chemotherapy-induced anemia in cancer patients receiving erythropoiesis-stimulating agents. Cochrane Database Syst Rev. 2016 Feb 4;(2):CD009624.

• 全文
• 摘要

44.  Hayat A. Safety issues with intravenous iron products in the management of anemia in chronic kidney disease. Clin Med Res. 2008 Dec;6(3-4):93-102.

• 全文
• 摘要

45.  Rozen-Zvi B, Gafter-Gvili A, Paul M, et al. Intravenous versus oral iron supplementation for the treatment of anemia in CKD: systematic review and meta-analysis. Am J Kidney Dis. 2008 Nov;52(5):897-906.

• 摘要

46.  Littlewood TJ, Alikhan R. The use of intravenous iron in patients with cancer-related anaemia. Br J Haematol. 2008 Jun;141(6):751-6.

• 摘要

47.  Auerbach M, Ballard H. Clinical use of intravenous iron: administration, efficacy, and safety. Hematology Am Soc Hematol Educ Program. 2010;2010:338-47.

• 全文
• 摘要

48.  Gasche C, Berstad A, Befrits R, et al. Guidelines on the diagnosis and management of iron deficiency and anemia in inflammatory bowel diseases. Inflamm Bowel Dis. 2007 Dec;13(12):1545-53.

• 摘要

49.  Kaltwasser JP, Kessler U, Gottschalk R, et al. Effect of recombinant human erythropoietin and intravenous iron on anemia and disease activity in rheumatoid arthritis. J Rheumatol. 2001 Nov;28(11):2430-6.

• 摘要

50.  National Kidney Foundation. KDOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease. Am J Kidney Dis. 2006 May;47(5 suppl 3):S11-145.

• 全文
• 摘要

51.  Jelkmann W. Developments in the therapeutic use of erythropoiesis stimulating agents. Br J Haematol. 2008 May;141(3):287-97.

• 摘要

52.  Singh AK, Szczech L, Tang KL, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006 Nov 16;355(20):2085-98.

• 全文
• 摘要

53.  Blau CA. Erythropoietin in cancer: presumption of innocence? Stem Cells. 2007 Aug;25(8):2094-7.

• 全文
• 摘要

54.  Schrijvers D, De Samblanx H, Roila F; ESMO Guidelines Working Group. Erythropoiesis-stimulating agents in the treatment of anaemia in cancer patients: ESMO clinical practice guidelines for use. Ann Oncol. 2010 May;21(suppl 5):v244-7.

• 全文
• 摘要

55.  Phrommintikul A, Haas SJ, Elsik M, et al. Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: a meta-analysis. Lancet. 2007 Feb 3;369(9559):381-8.

• 摘要

56.  Wish JB, Coyne DW. Use of erythropoiesis-stimulating agents in patients with anemia of chronic kidney disease: overcoming the pharmacological and pharmacoeconomic limitations of existing therapies. Mayo Clin Proc. 2007 Nov;82(11):1371-80.

• 摘要

57.  Corwin HL, Gettinger A, Fabian TC, et al. Efficacy and safety of epoetin alfa in critically ill patients. N Engl J Med. 2007 Sep 6;357(10):965-76.

• 全文
• 摘要

58.  Hebert PC, Fergusson DA. Can erythropoietin eradicate red cell transfusions in the critically ill? Crit Care Med. 2006 Sep;34(9):2490-1.

• 摘要

59.  Sun CC, Vaja V, Babitt JL, et al. Targeting the hepcidin-ferroportin axis to develop new treatment strategies for anemia of chronic disease and anemia of inflammation. Am J Hematol. 2012 Apr;87(4):392-400.

• 全文
• 摘要

60.  Bacchetta J, Zaritsky JJ, Lisse TS, et al. Vitamin D as a new regulator of iron metabolism: vitamin D suppresses hepcidin in vitro and in vivo. Nephrol Dial Transplant. 2012;27(suppl 2):ii28-30.

61.  Perlstein TS, Pande R, Berliner N, et al. Prevalence of 25-hydroxyvitamin D deficiency in subgroups of elderly persons with anemia: association with anemia of inflammation. Blood. 2011 Mar 10;117(10):2800-6.

• 全文
• 摘要

62.  Kumar VA, Kujubu DA, Sim JJ, et al. Vitamin D supplementation and recombinant human erythropoietin utilization in vitamin D-deficient hemodialysis patients. J Nephrol. 2011 Jan-Feb;24(1):98-105.

• 摘要

63.  Song SN, Tomosugi N, Kawabata H, et al. Down-regulation of hepcidin resulting from long-term treatment with an anti-IL-6 receptor antibody (tocilizumab) improves anemia of inflammation in multicentric Castleman disease. Blood. 2010 Nov 4;116(18):3627-34.

• 全文
• 摘要

64.  Lang VR, Englbrecht M, Rech J, et al. Risk of infections in rheumatoid arthritis patients treated with tocilizumab. Rheumatology (Oxford). 2012 May;51(5):852-7.

• 全文
• 摘要

65.  Schmid H, Schiffl H, Lederer SR. New strategies for managing anemia of chronic kidney disease. Cardiovasc Hematol Agents Med Chem. 2012 Dec;10(4):339-51.

• 摘要

66.  Kamioner D. Erythropoietin biosimilars currently available in hematology-oncology. Target Oncol. 2012 Mar;7(suppl 1):S25-8.

• 摘要

67.  Locatelli F, Del Vecchio L. An expert opinion on the current treatment of anemia in patients with kidney disease. Expert Opin Pharmacother. 2012 Mar;13(4):495-503.

• 摘要

68.  Debeljak N, Sytkowski AJ. Erythropoietin and erythropoiesis stimulating agents. Drug Test Anal. 2012 Nov;4(11):805-12.

• 摘要

69.  Gertz B, Kes P, Essaian A, et al. Epoetin theta: efficacy and safety of subcutaneous administration in anemic pre-dialysis patients in the maintenance phase in comparison to epoetin beta. Curr Med Res Opin. 2012 Jul;28(7):1101-10.

• 全文
• 摘要

70.  Hoffman R, Benz EJ Jr, Shattil SJ, et al. eds. Hematology: basics, principles, and practice. 4th ed. Philadelphia, PA: Elsevier; 2005.